Baghbanian Seyed Mohammad, Sahraian Mohammad Ali, Naser Moghadasi Abdorreza, Asgari Nasrin
Neurology Department; Booalisina Hospital, Mazandaran University of Medical Sciences; Sari, Iran.
Neurology Department, MS Research Centre, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Child Neurol. 2019 Summer;13(3):99-104.
The characteristics of paediatric neuromyelitis optica spectrum disorder (NMOSD) may indicate the degree of disability and identify factors that predict the response to treatment.
MATERIALS & METHODS: Among 114 NMOSD patients in an acquired demyelinating syndromes registry at the Sina Hospital, in Tehran, Iran, 10 paediatric NMOSD patients with longitudinal follow-up from 2005 to 2016 were retrospectively identified. The median time between disease onset and diagnosis was 18 months (range 1-108 months).
All patients had a relapsing course, which resulted in disability in six with severe visual impairment and functional blindness in one and impaired ambulation in five patients during follow-up. Azathioprine (AZA) was first drug of choice for prophylaxis, but in five patients new attacks occurred and therapy was switched to rituximab (RTX) with no further relapses after median two years (range 1-3 y) follow-up.
Paediatric onset of NMOSD was associated with severe attacks and poor response in 50 % of cases to AZA, RTX seemed to decrease the relapse rate.
儿童视神经脊髓炎谱系障碍(NMOSD)的特征可能表明残疾程度,并确定预测治疗反应的因素。
在伊朗德黑兰新浪医院获得性脱髓鞘综合征登记处的114例NMOSD患者中,回顾性确定了10例2005年至2016年进行长期随访的儿童NMOSD患者。疾病发作与诊断之间的中位时间为18个月(范围1 - 108个月)。
所有患者病程呈复发型,随访期间6例导致严重视力损害致残,1例功能性失明,5例行走功能受损。硫唑嘌呤(AZA)是预防的首选药物,但5例患者出现新的发作,治疗改为利妥昔单抗(RTX),中位随访两年(范围1 - 3年)后未再复发。
儿童期发病的NMOSD与严重发作相关,50%的病例对AZA反应不佳,RTX似乎可降低复发率。